What We're Reading: Page 113
Industry reads hand-picked by our editors
Jan 24, 2023
-
Bloomberg
Pharma CEOs Among Likely Targets for Democrats’ Subpoenas
-
Healthcare Dive
Amazon doubles down on generic drugs with new RxPass subscription
-
The Wall Street Journal
Drug Distributor AmerisourceBergen to Change Name to Cencora
-
The Timmerman Report
Biotech Needs to Get Back to Work in Person. Now.
Jan 23, 2023
-
The Boston Globe
‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year.
-
CNBC
FTC asks judge to hold ‘pharma bro’ Martin Shkreli in contempt of court for forming new drug firm
-
Financial Times
China’s drug-pricing policy impedes biotech profits
-
Fierce Pharma
Novo hit by 60 Minutes ‘paid’ Wegovy news program allegations
Jan 20, 2023
Jan 19, 2023
-
Axios
The struggle to contain the global threat of superbugs
-
The Wall Street Journal
Nursing Homes’ Use of Schizophrenia Drugs to Be Audited by U.S. Government
-
Evaluate Vantage
Biopharma’s stock market winners of 2022 revealed
Jan 18, 2023
Jan 17, 2023
-
The Wall Street Journal
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
-
FierceBiotech
NewAmsterdam’s Amgen castoff cuts LDL cholesterol in Phase 2
-
Bloomberg
Drugmakers Eli Lilly, AbbVie Leave UK Medicine-Pricing Agreement
-
The New York Times
The Father of the Abortion Pill
Previous
